Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent review (2011-2015)

References

• Ciuman RR. Inner ear symptoms and disease: pathophysiological understanding and therapeutic options. Med Sci Monit. 2013;19:1195–1210.
   PubMed Web of Science ®Google Scholar
• Muller U, Barr-Gillespie PG. New treatment options for hearing loss. Nat Rev Drug Discov. 2015;14:346–365.
   PubMed Web of Science ®Google Scholar
• El Kechai N, Agnely F, Mamelle E, et al. Recent advances in local drug delivery to the inner ear. Int J Pharm. 2015;494:83–101.
   PubMed Web of Science ®Google Scholar
• Otonomy, Inc. Modulation of gel temperature of poloxamer-containing sustained release formulations. US20120277199A1. 2012.
   Google Scholar
• Massachusetts Eye & Ear Infirmary. Osteoprotegerin in neuroprotection. US8716229B2. 2014.
   Google Scholar
• University of Maryland. Device and methods for directing agents to the middle ear and the inner ear including magnetic field. US20140073835A1. 2014.
   Google Scholar
• Otonomy, Inc. Methods for the treatment of pediatric otic disorders. US20150290124. 2015.
   Google Scholar
• Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity using corticosteroids and JNK inhibitors. US20130045957A1. 2013.
   Google Scholar
• University of Washington; Fred Hutchinson Cancer Research Center. Compositions and methods for protecting sensory hair cells. US20110135756A1. 2011.
   Google Scholar
• University of Washington; Fred Hutchinson Cancer Research Center. Compounds that protect against sensory hair cell death. US8232314B2. 2012.
   Google Scholar
• University of Pennsylvania. Chitosan-based matrixes for controlled-release delivery systems for inner ear drug application. US20130189241A1. 2013.
   Google Scholar
• Auris Medical AG. Methods and composition for treating and preventing tinnitus. US20150306178A1. 2015.
   Google Scholar
• Auris Medical AG. Pharmaceutical compositions for the treatment of inner ear disorders. US20150265532A1. 2015.
   Google Scholar
• Autifony Therapeutics Ltd. Triazole derivatives as Kv3 inhibitors. US20150111910A1. 2015.
   Google Scholar
• Otonomy, Inc.; The Regents of the University of California. Sustained release corticosteroid compositions for treatment of otic disorders. US20150313838A1. 2015.
   Google Scholar
• Otonomy, Inc.; The Regents of the University of California. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders. US20150313839A1. 2015.
   Google Scholar
• Otonomy, Inc.; The Regents of the University of California. Controlled-release ion channel modulator compositions and methods for the treatment of otic disorders. US20130150410A1. 2015.
   Google Scholar
• Otonomy, Inc.; The Regents of the University of California. Controlled release antimicrobial compositions and methods for the treatment of otic disorders. US20150150793A1. 2015.
   Google Scholar
• Autifony Therapeutics Limited. Hydantoin derivatives as Kv3 inhibitors. US20150157631A1. 2015.
   Google Scholar
• Autifony Therapeutics Limited. Hydantoin derivatives as Kv3 inhibitors for treatment of noise-induced hearing loss. WO2013175211A1. 2013.
   Google Scholar
• The Trustees Of Columbia University In The City Of New York. System and method to locally deliver therapeutic agent to inner ear. US20150265824A1. 2015.
   Google Scholar
• Hough Ear Institute. Composition and method for inner ear sensory hair cell regeneration and replacement. US20130210889A1. 2013.
   Google Scholar
• Otolanum AG Phantom phenomena treatment. US 20150099742A1. 2015.
   Google Scholar
• Sound Pharmaceuticals Inc. Methods and compositions for ameliorating the undesirable effects of chemotherapy. US20110065729A1. 2011.
   Google Scholar
• Charles Stark Draper Laboratory, Inc.. Massachusetts Eye & Ear Infirmary. Drug-eluting stapes prosthesis. US20150320551A1. 2015.
   Google Scholar
• Sanwa Kagaku Kenkyusho Co., Ltd. University of Tsukuba. Pharmaceutical for preventing or treating an inner ear disorder. US20130005698A1. 2013.
   Google Scholar
• Auris Medical AG. Methods using NMDA receptor antagonists for the treatment of tinnitus induced by cochlear excitotoxicity. US20150265552A1. 2015.
   Google Scholar
• Sensorion. Methods for treating vestibulotoxicty. US20150087677A1. 2015.
   Google Scholar
• House Ear Institute; Otonomy, Inc. Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor. US9173865B2. 2015.
   Google Scholar
• The Charles Stark Draper Laboratory, Inc.; Massachusetts Eye & Ear Infirmary. Drug delivery apparatus US20150157837A1. 2015.
   Google Scholar
• Massachusetts Eye & Ear Infirmary. Treating hearing loss using certain gamma secretase inhibitors. WO2014039781A1. 2014.
   Google Scholar
• Massachusetts Eye & Ear Infirmary. Methods and compositions comprising histone deacetylase (HDAC) inhibitors in combination with other therapeutics for treating subjects at risk for or with sensorineural hearing loss. WO2015168149A2. 2015.
   Google Scholar
• Sensorion. Calcineurin inhibitors for use in the treatment of lesional vestibular disorders US20150057233A1. 2015.
   Google Scholar
• Opko Curna LLC Treatment of atonal homolog 1-related diseases by inhibition of natural antisense transcript to ATOH1. US20150038553A1. 2015.
   Google Scholar
• Massachusetts Eye and Ear Infirmary. Methods and compositions for regenerating inner ear hair cells and/or supporting cells. US20150209406A1. 2015.
   Google Scholar
• Autifony Therapeutics Ltd. Novel compounds. US20150336936A1. 2015.
   Google Scholar
• Autifony Therapeutics Ltd. Imidazolinedione derivatives. US20150018377A1. 2015.
   Google Scholar
• Quark Pharmaceuticals, Inc., USA. Double-stranded RNA combination therapy targeting genes HES1, HES5, HEY2, CDKN1B, and NOTCH1, for use in treating hearing and balance disorders. US20150126586A1. 2015.
   Google Scholar
• Ayoob AM, Borenstein JT. The role of intracochlear drug delivery devices in the management of inner ear disease. Expert Opin Drug Del. 2015;12:465–479.
   PubMed Web of Science ®Google Scholar
• Swan EE, Mescher MJ, Sewell WF, et al. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev. 2008;60:1583–1599.
   PubMed Web of Science ®Google Scholar
• Hoskison E, Daniel M, Al-Zahid S, et al. Drug delivery to the ear. Ther Deliv. 2013;4:115–124.
   PubMedGoogle Scholar
• Chittka L, Brockmann A. Perception space–the final frontier. PLoS Biol. 2005;3:e137.
   PubMed Web of Science ®Google Scholar
• Tritsch NX, Yi E, Gale JE, et al. The origin of spontaneous activity in the developing auditory system. Nature. 2007;450:50–55.
   PubMed Web of Science ®Google Scholar
• Van Der Jeught S, Dirckx JJJ, Aerts JRM, et al. Full-field thickness distribution of human tympanic membrane obtained with optical coherence tomography. Jaro-J Assoc Res Oto. 2013;14:483–494.
   PubMed Web of Science ®Google Scholar
• Goycoolea MV. Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol. 2001;121:437–447.
   PubMed Web of Science ®Google Scholar
• Okuno H, Sando I. Anatomy of the round window. A histopathological study with a graphic reconstruction method. Acta Otolaryngol. 1988;106:55–63.
   PubMed Web of Science ®Google Scholar
• Schiller JS, Lucas JW, Ward BW, et al. Summary health statistics for U.S. adults: national health interview survey, 2010. Vital Health Stat. 2012;252:1–207.
   Google Scholar
• Angeli S, Lin X, Liu XZ. Genetics of hearing and deafness. Anat Rec (Hoboken). 2012;295:1812–1829.
   PubMedGoogle Scholar
• Schuknecht HF, Gacek MR. Cochlear pathology in presbycusis. Ann Otol Rhinol Laryngol. 1993;102:1–16.
   PubMed Web of Science ®Google Scholar
• Kujawa SG, Liberman MC. Acceleration of age-related hearing loss by early noise exposure: evidence of a misspent youth. J Neurosci. 2006;26:2115–2123.
   PubMed Web of Science ®Google Scholar
• Viana LM, O’Malley JT, Burgess BJ, et al. Cochlear neuropathy in human presbycusis: confocal analysis of hidden hearing loss in post-mortem tissue. Hear Res. 2015;327:78–88.
   PubMed Web of Science ®Google Scholar
• Kujawa SG, Liberman MC. Adding insult to injury: cochlear nerve degeneration after “temporary” noise-induced hearing loss. J Neurosci. 2009;29:14077–14085.
   PubMed Web of Science ®Google Scholar
• Nadol JB Jr. Patterns of neural degeneration in the human cochlea and auditory nerve: implications for cochlear implantation. Otolaryngol Head Neck Surg. 1997;117:220–228.
   PubMed Web of Science ®Google Scholar
• Wan G, Gomez-Casati ME, Gigliello AR, et al. Neurotrophin-3 regulates ribbon synapse density in the cochlea and induces synapse regeneration after acoustic trauma. Elife. 2014;3:e03564.
   PubMed Web of Science ®Google Scholar
• Kuwahara A, Hirabayashi Y, Knoepfler PS, et al. Wnt signaling and its downstream target N-myc regulate basal progenitors in the developing neocortex. Development. 2010;137:1035–1044.
   PubMed Web of Science ®Google Scholar
• Shore SE, Roberts LE, Langguth B. Maladaptive plasticity in tinnitus - triggers, mechanisms and treatment. Nat Reviews Neurol. 2016;12:150–160.
   PubMed Web of Science ®Google Scholar
• Langguth B, Kreuzer PM, Kleinjung T, et al. Tinnitus: causes and clinical management. Lancet Neurol. 2013;12:920–930.
   PubMed Web of Science ®Google Scholar
• Slattery WH, Fisher LM, Iqbal Z, et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg. 2005;133:251–259.
   PubMed Web of Science ®Google Scholar
• Garduno-Anaya MA, Couthino De Toledo H, Hinojosa-Gonzalez R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere’s disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg. 2005;133:285–294.
   PubMed Web of Science ®Google Scholar
• Goebel G, Kahl M, Arnold W, et al. 15-year prospective follow-up study of behavioral therapy in a large sample of inpatients with chronic tinnitus. Acta Otolaryngol Suppl. 2006;126:70–79.
   Google Scholar
• Thompson TL, Amedee R. Vertigo: a review of common peripheral and central vestibular disorders. Ochsner J. 2009;9:20–26.
   PubMedGoogle Scholar
• Harcourt J, Barraclough K, Bronstein AM. Meniere’s disease. Bmj. 2014;349:g6544.
   PubMed Web of Science ®Google Scholar
• Gates GA. Meniere’s disease review 2005. J Am Acad Audiol. 2006;17:16–26.
   PubMed Web of Science ®Google Scholar
• Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends Neurosci. 2001;24:517–526.
   PubMed Web of Science ®Google Scholar
• Von Hehn CA, Bhattacharjee A, Kaczmarek LK. Loss of Kv3.1 tonotopicity and alterations in cAMP response element-binding protein signaling in central auditory neurons of hearing impaired mice. J Neurosci. 2004;24:1936–1940.
   PubMed Web of Science ®Google Scholar
• Autifony Drug Development: Pipeline. Autifony Therapeutics, Ltd, 2016. Available from: http://www.autifonytherapeutics.com/autifony-pipeline.asp [cited 2016 April 25].
   Google Scholar
• Gribkoff VK. The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update. Expert Opin Ther Targets. 2008;12:565–581.
   PubMed Web of Science ®Google Scholar
• Kharkovets T, Dedek K, Maier H, et al. Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness. Embo J. 2006;25:642–652.
   PubMed Web of Science ®Google Scholar
• Kharkovets T, Hardelin JP, Safieddine S, et al. KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A. 2000;97:4333–4338.
   PubMed Web of Science ®Google Scholar
• Kubisch C, Schroeder BC, Friedrich T, et al. KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell. 1999;96:437–446.
   PubMed Web of Science ®Google Scholar
• Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci. 2013;9:948–959.
   PubMed Web of Science ®Google Scholar
• Bing D, Lee SC, Campanelli D, et al. Cochlear NMDA receptors as a therapeutic target of noise-induced tinnitus. Cell Physiol Biochem. 2015;35:1905–1923.
   PubMed Web of Science ®Google Scholar
• AM-101. Auris Medical, 2016. Available from: http://www.aurismedical.com/product-candidates/am-101 [cited 2016 April 25].
   Google Scholar
• Bermingham-McDonogh O, Rubel EW. Hair cell regeneration: winging our way towards a sound future. Curr Opin Neurobiol. 2003;13:119–126.
   PubMed Web of Science ®Google Scholar
• Corwin JT, Oberholtzer JC. Fish n’ chicks: model recipes for hair-cell regeneration?. Neuron. 1997;19:951–954.
   PubMed Web of Science ®Google Scholar
• Rubel EW, Fritzsch B. Auditory system development: primary auditory neurons and their targets. Annu Rev Neurosci. 2002;25:51–101.
   PubMed Web of Science ®Google Scholar
• Bermingham NA, Hassan BA, Price SD, et al. Math1: an essential gene for the generation of inner ear hair cells. Science. 1999;284:1837–1841.
   PubMed Web of Science ®Google Scholar
• Izumikawa M, Minoda R, Kawamoto K, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med. 2005;11:271–276.
   PubMed Web of Science ®Google Scholar
• Yang SM, Chen W, Guo WW, et al. Regeneration of stereocilia of hair cells by forced Atoh1 expression in the adult mammalian cochlea. PLoS One. 2012;7:e46355.
   PubMed Web of Science ®Google Scholar
• Baker K, Brough DE, Staecker H. Repair of the vestibular system via adenovector delivery of Atoh1: a potential treatment for balance disorders. Adv Otorhinolaryngol. 2009;66:52–63.
   PubMedGoogle Scholar
• Schlecker C, Praetorius M, Brough DE, et al. Selective atonal gene delivery improves balance function in a mouse model of vestibular disease. Gene Ther. 2011;18:884–890.
   PubMed Web of Science ®Google Scholar
• Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene. 2005;24:6333–6344.
   PubMed Web of Science ®Google Scholar
• Driver EC, Sillers L, Coate TM, et al. The Atoh1-lineage gives rise to hair cells and supporting cells within the mammalian cochlea. Dev Biol. 2013;376:86–98.
   PubMed Web of Science ®Google Scholar
• Roberson DW, Alosi JA, Cotanche DA. Direct transdifferentiation gives rise to the earliest new hair cells in regenerating avian auditory epithelium. J Neurosci Res. 2004;78:461–471.
   PubMed Web of Science ®Google Scholar
• Mizutari K, Fujioka M, Hosoya M, et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron. 2013;77:58–69.
   PubMed Web of Science ®Google Scholar
• Mulvaney J, Dabdoub A. Atoh1, an essential transcription factor in neurogenesis and intestinal and inner ear development: function, regulation, and context dependency. J Assoc Res Otolaryngol. 2012;13:281–293.
   PubMed Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125–140.
   PubMed Web of Science ®Google Scholar
• De Lau W, Peng WC, Gros P, et al. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 2014;28:305–316.
   PubMed Web of Science ®Google Scholar
• Michaelidis TM, Lie DC. Wnt signaling and neural stem cells: caught in the Wnt web. Cell Tissue Res. 2008;331:193–210.
   PubMed Web of Science ®Google Scholar
• Charles Stark Draper Laboratory, Inc.. Massachusetts Eye & Ear Infirmary. Drug-eluting staples prosthesis. US20150320551A1. 2015.
   Google Scholar
• Medicine to preserve hearing. Oricula Therapeutics, LLC, 2016. Available from: http://www.oricularx.com/#!products/cee5 [cited 2016 April 25].
   Google Scholar
• Oishi N, Schacht J. Emerging treatments for noise-induced hearing loss. Expert Opin Emerg Drugs. 2011;16:235–245.
   PubMed Web of Science ®Google Scholar
• Choi YH, Miller JM, Tucker KL, et al. Antioxidant vitamins and magnesium and the risk of hearing loss in the US general population. Am J Clin Nutr. 2014;99:148–155.
   PubMed Web of Science ®Google Scholar
• Campbell KC, Meech RP, Klemens JJ, et al. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res. 2007;226:92–103.
   PubMed Web of Science ®Google Scholar
• Campbell K, Claussen A, Meech R, et al. D-methionine (D-met) significantly rescues noise-induced hearing loss: timing studies. Hear Res. 2011;282:138–144.
   PubMed Web of Science ®Google Scholar
• Wilson C, Campell KCM. Phase 3 clinical trial: d-methionine to reduce noise-induced hearing. Bethesda (MD): National Library of Medicine (US). 2011. [cited 2016 April 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT01345474
   Google Scholar
• Ebetino FH, Hogan AM, Sun S, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20–33.
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 2001;7:613–635.
   PubMed Web of Science ®Google Scholar
• Shimamura M, Nakagami H, Osako MK, et al. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proc Natl Acad Sci U S A. 2014;111:8191–8196.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Satou T, Itoh T, et al. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol. 2012;361:219–231.
   PubMed Web of Science ®Google Scholar
• Kao SY, Kempfle JS, Jensen JB, et al. Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. Neurobiol Dis. 2013;56:25–33.
   PubMed Web of Science ®Google Scholar
• Sabapathy K. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 2012;106:145–169.
   PubMed Web of Science ®Google Scholar
• Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001;98:13681–13686.
   PubMed Web of Science ®Google Scholar
• Wang J, Van De Water TR, Bonny C, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci. 2003;23:8596–8607.
   PubMed Web of Science ®Google Scholar
• Wang J, Ruel J, Ladrech S, et al. Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals. Mol Pharmacol. 2007;71:654–666.
   PubMed Web of Science ®Google Scholar
• Zine A. van de Water TR. The MAPK/JNK signalling pathway offers potential therapeutic targets for the prevention of acquired deafness. Curr Drug Targets CNS Neurol Disord. 2004;3:325–332.
   PubMedGoogle Scholar
• Grindal TC, Sampson EM, Antonelli PJ. AM-111 prevents hearing loss from semicircular canal injury in otitis media. Laryngoscope. 2010;120:178–182.
   PubMed Web of Science ®Google Scholar
• Coleman JK, Littlesunday C, Jackson R, et al. AM-111 protects against permanent hearing loss from impulse noise trauma. Hear Res. 2007;226:70–78.
   PubMed Web of Science ®Google Scholar
• Eshraghi AA, Gupta C, Van De Water TR, et al. Molecular mechanisms involved in cochlear implantation trauma and the protection of hearing and auditory sensory cells by inhibition of c-Jun-N-terminal kinase signaling. Laryngoscope. 2013;123(Suppl 1):S1–14.
   PubMed Web of Science ®Google Scholar
• AM-111. Auris Medical, 2016. Available from: http://www.aurismedical.com/product-candidates/am-111 [cited 2016 April 25].
   Google Scholar
• Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev. 2000;80:1483–1521.
   PubMed Web of Science ®Google Scholar
• Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191:5785–5791.
   PubMed Web of Science ®Google Scholar
• Hu A, Parnes LS. Intratympanic steroids for inner ear disorders: a review. Audiol Neurootol. 2009;14:373–382.
   PubMed Web of Science ®Google Scholar
• Hamid M, Trune D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg. 2008;16:434–440.
   PubMed Web of Science ®Google Scholar
• Hill SL 3rd, Digges EN, Silverstein H. Long-term follow-up after gentamicin application via the Silverstein MicroWick in the treatment of Meniere’s disease. Ear Nose Throat J. 2006;85(494):496, 498.
   Google Scholar
• Van Wijck F, Staecker H, Lefebvre PP. Topical steroid therapy using the silverstein microwick (TM) in sudden sensorineural hearing loss after failure of conventional treatment. Acta Oto-Laryngol. 2007;127:1012–1017.
   PubMed Web of Science ®Google Scholar
• Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23:H41–56.
   PubMed Web of Science ®Google Scholar
• Heldin P, Asplund T, Ytterberg D, et al. Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. Biochem J. 1992;283:165–170.
   PubMed Web of Science ®Google Scholar
• Klouda L. Thermoresponsive hydrogels in biomedical applications: A seven-year update. Eur J Pharm Biopharm. 2015;97:338–349.
   PubMed Web of Science ®Google Scholar
• Hu L, Sun Y, Wu Y. Advances in chitosan-based drug delivery vehicles. Nanoscale. 2013;5:3103–3111.
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463–469.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord JL, Agnely F, et al. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709–2728.
   PubMed Web of Science ®Google Scholar
• Wang X, Dellamary L, Fernandez R, et al. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. Audiol Neuro-Otology. 2009;14:393-401.
   PubMed Web of Science ®Google Scholar
• OTO-104. Otonomy, Inc, 2016. Available from: http://www.otonomy.com/pipeline/oto-104/ [cited 2016 April 25].
   Google Scholar
• OTO-311. Otonomy, Inc, 2016. Available from: http://www.otonomy.com/pipeline/oto-311/ [cited 2016 April 25].
   Google Scholar
• Clinical Trials. Otonomy, Inc, 2016. Available from: http://www.otonomy.com/pipeline/clinical-trials/ [cited 2016 April 25].
   Google Scholar
• Shapiro B, Kulkarni S, Nacev A, et al. Shaping magnetic fields to direct therapy to ears and eyes. Annu Rev Biomed Eng. 2014;16:455–481.
   PubMed Web of Science ®Google Scholar
• Shapiro B, Depireux D, Sarwar A, et al. Pre-clinical development of magnetic delivery of therapy to middle and inner ears. ENT & Audiology News. 2014;23:54–56.
   Google Scholar
• Liktor B, Szekanecz Z, Batta TJ, et al. Perspectives of pharmacological treatment in otosclerosis. Eur Arch Otorhinolaryngol. 2013;270:793–804.
   PubMed Web of Science ®Google Scholar
• Wegner I, Verhagen JJ, Stegeman I, et al. A systematic review of the effect of piston diameter in stapes surgery for otosclerosis on hearing results. Laryngoscope. 2016;126:182–190.
   PubMed Web of Science ®Google Scholar
• Klickstein L, CGF166 Atonal Gene Therapy for Hearing Loss & Vestibular Dysfunction: Review of NIH OBA protocol #1310-1260. 2013. Available from: http://osp.od.nih.gov/sites/default/files/1_1260_CGF166_Klickstein.pdf [cited 2016 April 25].
   Google Scholar
• Kopke RD, Wassel RA, Mondalek F, et al. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol Neurootol. 2006;11:123–133.
   PubMed Web of Science ®Google Scholar
• Dormer KJ, Awasthi V, Galbraith W, et al. Magnetically-targeted, technetium 99m-labeled nanoparticles to the inner ear. J Biomed Nanotechnol. 2008;4:174–184.
   Web of Science ®Google Scholar
• Sensenig R, Sapir Y, MacDonald C, et al. Magnetic nanoparticle-based approaches to locally target therapy and enhance tissue regeneration in vivo. Nanomedicine. 2012;7:1425–1442.
   PubMed Web of Science ®Google Scholar
• Sarwar A, Lee R, Depireux DA, et al. Magnetic injection of nanoparticles into rat inner ears at a human head working distance. IEEE Trans Magn. 2013;49:440–452.
   Web of Science ®Google Scholar
• Third rock ventures launches decibel therapeutics with $52 million series a financing to discover new medicines to protect, repair, and restore hearing. Decibel Therapeutics, Inc, 2015. [cited 2016 April 25]. Available from: https://decibeltx.com/
   Google Scholar
• Rubel EW, Furrer SA, Stone JS. A brief history of hair cell regeneration research and speculations on the future. Hear Res. 2013;297:42–51.
   PubMed Web of Science ®Google Scholar
• Bramhall NF, Shi F, Arnold K, et al. Lgr5-positive supporting cells generate new hair cells in the postnatal cochlea. Stem Rep. 2014;2:311–322.
   PubMed Web of Science ®Google Scholar
• Ku YC, Renaud NA, Veile RA, et al. The transcriptome of utricle hair cell regeneration in the avian inner ear. J Neurosci. 2014;34:3523–3535.
   PubMed Web of Science ®Google Scholar
• Jahan I, Pan N, Fritzsch B. Opportunities and limits of the one gene approach: the ability of Atoh1 to differentiate and maintain hair cells depends on the molecular context. Front Cell Neurosci. 2015;9:26.
   PubMed Web of Science ®Google Scholar
• Henley DB, Sundell KL, Sethuraman G, et al. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin. 2014;30:2021–2032.
   PubMed Web of Science ®Google Scholar
• De Strooper B. Lessons from a failed gamma-secretase Alzheimer trial. Cell. 2014;159:721–726.
   PubMed Web of Science ®Google Scholar